Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tris Pharma Inc.

www.trispharma.com

Latest From Tris Pharma Inc.

Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar

The latest drug development news and highlights from our FDA Performance Tracker.

Approvals Review Pathway

Stockwatch: Third-Quarter Earnings Portents

Negative third-quarter earnings announcements from Vertex and Illumina are not good portents for an end of year life science rally and the absence of helpful positive announcements from Valeant and Gilead does not bode well either.

Sales & Earnings Companies

PIPELINE WATCH: Three Approvals, Five Filings And Two Launches

This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.

Pipeline Watch Approvals

Vernalis Raises $58m To Close Potential Funding Gap

Slower than expected US sales of its first long-acting liquid cough-and-cold formulation, and improved visibility on its future US infrastructure costs, has prompted UK-based Vernalis to raise funds from existing investors to support further product launches and to reach the goal of sustainable profitability.

Strategy Respiratory
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tris Pharma Inc.
  • Senior Management
  • Ketan Mehta, Pres. & CEO
    Mahdi Fawzi, PhD, EVP, CSO
    Jonathan Berlent, VP, Bus. Dev.
    Yu-Hsing Tu, VP, R&D
    Adam Drapczuk, Dir., Fin.
  • Contact Info
  • Tris Pharma Inc.
    Phone: (732) 940-2800
    2033 Route 130, Ste. D
    Monmouth Junction , NJ 08852
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register